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The safety and immunogenicity of TETRActHIB (a vaccine 
combining diphtheria and tetanus toxoids-pertussis vaccine 
(DTP) with Haemophilus influenzae type b (Hib) conjugate 
vaccine (polyribosyl ribitol phosphate conjugated to tetanus 
protein) (PRP-T)) was assessed in 131 Cape Town infants 
immunised at 6, 10 and 14 weeks of age. Serological 
responses to all component antigens were measured before 
the first dose and at 18 weeks of age. In addition, anti-PRP 
antibodies were measured at 9 and 18 months of age to 
determine long-term immunogenicity. The vaccine was well 
tolerated by infants and no significant side-effects were 
reported. Responses to Hib at 18 weeks of age were good in 
that most infants achieved a level of anti-PRP antibodies 
<". 0.15 µg/ml, indicative of short-term protection, and 70% 
achieved a level<". 1 µg/ml, indicative of long-term 
protection. The proportions of children with protective 
levels<". 0.15 µg/ml and<". 1 µg/ml were similar at 9 and 18 
months of age, i.e. approximately 75% and 45%, 
respectively. Responses to tetanus and diphtheria toxoids 
were excellent and all infants achieved protective 
serological levels. Responses to pertussis were moderate in 
that approximately 65% achieved 'protective' serum levels 
of pertussis agglutinins, i.e. titres <". 320. In conclusion, this 
study has shown that the DTP /PRP-T vaccine is safe, 
immunogenic and well tolerated in infants immunised at 6, 
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10 and 14 weeks of age. TETRActHIB is therefore suitable for 
inclusion in the World Health Organisation Expanded 
Programme on Immunisation (WHO EPI) schedule. 
S Afr Med J 2002; 92: 53-57. 
Haemophilus influenzae type b (Hib) is one of the most common 
causes of serious bacterial infections in children under 5 years 
of age. Serious Hib infections manifest as meningitis, 
epiglottitis, pneumonia, arthritis, cellulitis, and other forms of 
bacteraemic disease. In Europe and the USA the annual 
incidence of invasive Hib disease varied from 25 to 80/100 000 
children under 5 years before the introduction of Hib conjugate 
vaccines. 1•2 In Alaskan native or Australian native populations, 
the incidence reached 500 cases/100 000 children.3" 
In South Africa, Hib is a major cause of childhood morbidity 
and mortality. Approximately 70% of cases occur in children 
under 1 year of age. The incidence of disease in these children 
is 169/100 000, and overall case fatality is approximately 9%. 
One study estimated that 1 in 250 children will develop 
invasive disease in the first year of life and that 1 in 11 children 
with the disease will die.' 
Since the introduction of the conjugate vaccines in the early 
1990s, the incidence of Hib disease has declined dramatically 
in developed countries. In fact, the disease has been virtually 
eliminated in parts of the USA and Europe.6-8 In developing 
countries, however, experience with conjugate vaccines is 
limited. Studies from the Gambia'·10 and Chile11 •12 have indicated 
that the vaccines are immunogenic and protect against Hib 
disease when administered to children from the age of 2 
months. Nevertheless, few studies have evaluated the safety 
and efficacy of these vaccines when given at an early age, i.e. at 
6, 10 and 14 weeks, the current World Health Organisation 
(WHO) Expanded Programme on Immunisation (EPI) schedule 
of vaccination. Recent studies from the Philippines13 and Cape 
Town" have indicated that such vaccines are safe and 
immunogenic when administered according to this schedule. 
Hib vaccine can be administered in combination with DTP 
vaccine. One such combination vaccine is TETRActHIB, which 
consists of DTP extemporaneously combined with polyribosyl 
ribitol phosphate conjugated to tetanus protein (PRP-T) 
(capsular polysaccharide extracted and purified from Hib and 
conjugated to a tetanus toxoid carrier). Studies of the various 
combined vaccines indicate that they are immunogenic and 
safe when administered to infants from the age of 2 months.15-18 
However, there are no published data from Africa for infants 
immunised at 6, 10 and 14 weeks of age, which is the WHO's 
recommended schedule for DTP immunisation. Data from the 
Philippines indicate that the vaccines are immunogenic when 
administered according to this schedule." 
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The objective of the present study was to assess the safety 
and immunogenicity of TETRActHIB vaccine (lyophilised 
PRP-T vaccine reconstituted with the liquid DTP vaccine) in 6-
week-old South African infants. 
METHODS AND STUDY POPULATION 
Study design and ethical considerations 
This study was an open, non-comparative, phase IV trial 
conducted at two primary care clinics in Cape Town, South 
Africa. The Research and Ethics Committee of the Faculty of 
Medicine, University of Cape Town, and the Medicines Control 
Council, South Africa, approved the study protocol. Study 
procedures complied with Good Clinical Practice and the 
Declaration of Helsinki. Written informed consent was 
obtained from a parent or legal guardian for each child 
enrolled in this study. 
Subjects 
Healthy 6-week-old infants of either sex, born after 37 weeks of 
pregnancy with a birth weight of > 2 500 g, were considered for 
this study. Non-inclusion criteria were prior administration of 
Hib, DTP or hepatitis B vaccine, an acute disease, known 
congenital or acquired immunodeficiency (including HIV 
infection), family history of sudden infant death syndrome 
(SIDS) or receiving immunosuppressive drug therapy. Any 
child presenting with fever at the time of enrolment was not 
eligible for inclusion. 
From February 1997 to September 1997, 131 infants were 
included in this study. Upon inclusion, each infant was 
assigned an identification number that corresponded to a 
package containing the study vaccine. Each infant received 
TETRActHIB vaccine, according to the EPI immunisation 
schedule, i.e. at 6, 10 and 14 weeks of age. Children were given 
oral polio vaccine (Polioral, Chiron, Italy) and hepatitis B 
vaccine (Hepaccine, Cheil Foods and Chemicals, South Korea) 
concomitant with the study vaccine. 
Vaccines 
TETRActHIB (batch no. 652, Aventis Pasteur (formerly, Pasteur 
Merieux Connaught) Lyon, France) comprises a lyophilised 
Hib capsular polysaccharide tetanus conjugate vaccine 
(ActHIB, Aventis Pasteur) that is reconstituted with liquid DTP 
(Aventis Pasteur). 
Each 0.5 ml dose of DTP, presented in a pre-filled syringe 
fitted with a 16 mm needle, contains purified inactivated 
diphtheria toxoid (;::: 30 IU), purified tetanus toxoid (;::: 60 IU) 
and inactivated Bordetella pertussis suspension (;::: 4 IU). The 
vaccine also contains aluminium hydroxide, thiomersal, and 
buffer solution. The lyophilised Hib conjugate vaccine contains 
10 µg of Hib capsular polysaccharide, PRP, conjugated to a 
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tetanus toxoid carrier protein. Each dose also contains 0.6 mg 
tris (HCI) and 42.5 mg sucrose. 
Vaccine was reconstituted immediately before administration 
and was given by intramuscular injection into the anterolateral 
aspect of the thigh. Hepatitis B vaccine was administered by 
intramuscular injection into the opposite thigh. 
Procedures 
Immediately before the first dose of vaccine, a blood sample 
(4 ml) was taken from each infant. The vaccine was then 
administered and the infant was kept under supervision 
during the next 30 minutes to detect any immediate reaction to 
vaccination. The parents were instructed on how to use a 
digital thermometer and were given a diary card to record any 
local or systemic reactions during the 3 days following each 
dose of vaccine. Infants were brought back to the study centre 
at 10 and 14 weeks of age for their second and third 
vaccinations. At each visit, a medical history was taken to 
ensure that there were no contraindications to continuation in 
the trial. Parents were asked to bring their child back to the 
centre for further blood sampling at 9 and 18 months of age. 
Laboratory investigations 
All serological analyses were performed by the Immunology 
Laboratory of the Institute of Child Health (ICH), University of 
Cape Town. The anti-PRP responses were measured by means 
of a radio-immunological assay (RIA) derived from the Farr 
method, using an iodine125-labelled polysaccharide.20 Anti-PRP 
antibody levels were expressed in µg/ml. Antibodies to 
diphtheria and tetanus toxoids were measured using an 
enzyme-linked immunosorbent assay (ELISA) sandwich 
assay.21" 2 Anti-pertussis antibodies were measured using a 
conventional agglutination reaction.23 All measurements were 
performed on samples taken just before vaccination and 
1 month after the third vaccine dose. Additional, anti-PRP 
antibodies titres were measured at 9 and 18 months of age. 
For quality control purposes the anti-PRP antibody 
measurements were repeated on the first 25 samples obtained 
at 6 and 18 weeks of age at the Clinical Sero-immunology 
Laboratory, Aventis Pasteur, Val de Reuil, France, using the 
same RIA method as that used in the ICH laboratory. 
Data analysis 
The main objective of this study was to confirm that the Hib 
conjugate vaccine, in combination with DTP vaccine, elicited a 
satisfactory immune response when given at 6, 10 and 14 
weeks of age. 
PRP antibody levels were described for the study population 
as geometric mean titres (GMT) before vaccination (6 weeks of 
age), 1 month after the third vaccine dose (18 weeks), and at 
9 and 18 months of age. The proportions of infants with PRP 
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antibody levels~ 0.15 µg/ml, indicative of short-term 
protection, and 2'. 1.0 µg/ml, indicative of long-term protection, 
were calculated at each blood sampling time. GMTs for tetanus, 
diphtheria and pertussis antibodies were calculated at 6 and 18 
weeks of age, as were the proportions of infants with 
seroprotective levels of antibodies (0.01 IU I ml for tetanus and 
diphtheria antitoxins, and ~ 320 for pertussis agglutinins). 
Safety data were described in terms of the percentage of 
children who reported adverse reactions at any time during the 
first 72 hours following immunisation. Results are shown here 
for each sign/ symptom reported. 
Data were collated and analysed using Epi-Info v6.04 
(Centers for Disease Control, Atlanta) and Statistica packages 
(StatSoft, USA). 
RESULTS 
One hundred and thirty-one children were enrolled in the 
study; 2 children were withdrawn subsequently for personal 
reasons (mother refused to let child give second blood sample). 
The safety data are presented for 129 children. The serological 
data are presented for the 112 children for whom serum 
samples were obtained at all time points. 
The vaccine was well tolerated by all the infants. No 
immediate adverse events were noted within the first 30 
minutes following immunisation. Local and systemic reactions 
within 72 hours following immunisation are reported in 
Table I. Most reactions were mild, resolving within 72 hours, 
and none had any sequelae. Pain at the injection site and crying 
Table I. Percentage of children (N = 129) with reported adverse 
reactions at any time during the first 72 hours following 
immunisation with DTP/PRP-T combination vaccine at 6, 10 and 
14 weeks of age 
Post-vacc 1 Post-vacc 2 Post-vacc 3 
Local reactions 
Pain* 
Little 40.8 27.7 23.9 
Significant 12.3 8.5 7.7 
Redness 21.6 18.5 21.6 
Swelling 24.6 20.8 16.9 
Systemic reactions 
Temp > 37.5°C 7.7 6.2 7.8 
Crying 
< 1 hour 50.8 31.6 32.3 
> 1 hour 10.1 4.7 5.5 
Reduced activity 11.6 12.3 13.1 
Poor feeding 13.9 10.9 12.3 
Vomiting 8.4 3.1 3.9 
Diarrhoea 14.6 13.1 13.9 
*Little and significant were respectively defined as baby crying briefly or crying a lot 
when the injection site was touched. 
Vacc = vaccination. 
for a short period following injection were the most frequently 
reported events. Redness and swelling at the injection site 
exceeding 2.5 cm occurred only in 3 and 4 children respectively. 
A high fever(> 39.5°C) was reported in only 1 instance after a 
third vaccine dose. 
No deaths were reported during the study period. Three 
children were hospitalised (more than 14 days following 
immunisation) during the study period. The reason for 
hospitalisation in each instance was diarrhoea, bronchiolitis 
and pneumonia. No hospitalisation was considered to be 
related to the immunisation. 
Anti-PRP antibody results obtained at 6 weeks of age (before 
immunisation), 18 weeks (4 weeks after the third vaccination), 
9 months and 18 months of age are given in Table II. Responses 
to Hib after the third vaccine dose were good in that most 
infants achieved a level of anti-PRP antibodies> 0.15 µg/ml 
and 69% achieved a level> 1 µg/ml. Although antibody titres 
tended to drop during the first 5 months after immunisation, 
the proportions of children with levels~ 0.15 µg/ml and 
~ 1.0 µg/ml at 9 and 18 months of age remained more or less 
stable (78 - 73% and 46 - 43%, respectively). 
Table II. Anti-PRP antibody levels in children immunised with 
three doses of DTP/PRP-T vaccine given at 6, 10 and 14 weeks of 
age; serological examination was done at 6 and 18 weeks, and at 9 
and 18 months of age (N = 112) 
Age 6 wks 18 wks 9 mo. 18 mo. 
Geometric mean titre 0.14 1.76 0.61 0.62 
Minimum 0.04 0.08 0.01 0.01 
Maximum 7.41 69.12 217.6 563.2 
% with level> 0.15 µg/ml 43.7 95.5 78.6 75.9 
% with level> 1.0 µg/ml 13.6 69.1 46.4 43.7 
Responses to tetanus, diphtheria and pertussis at 6 and 18 
weeks of age are shown in Table III. All infants achieved 
protective serological levels to tetanus and diphtheria. 
Responses to pertussis were moderate in that approximately 
65% achieved 'protective' serum levels of pertussis agglutinins, 
i.e. a titre > 320. 
The anti-PRP data from the ICH and Aventis Pasteur 
laboratories are shown in Table VI. The GMT results from the 
Aventis Pasteur laboratory were significantly higher than 
those from the ICH laboratory (P < 0.001). However, there was 
a good correlation between the two laboratories; r = 0.96 (0.91 -
0.98) for the first specimen and r = 0.83 (0.64 - 0.92) for the 
second specimen. In addition, the proportions of children with 
post-immunisation levels~ 0.15 and~ 1.0 ug/ml were 
identical. 
DISCUSSION 
This study was done to determine the safety and 
immunogenicity of a combination Hib-DTP vaccine when 
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Table III.Tetanus, diphtheria and pertussis antibody levels in 
children immunised with three doses of DTP/PRP-T vaccine given 
at 6, 10 and 14 weeks of age; results are shown before immunisation 
at 6 and 18 weeks of age 
6weeks 18 weeks 
Anti-tetanus toxin antibody 
Geometric mean titre 0.06 6.32 
Minimum < 0.001 0.60 
Maximum 4.91 71.3 
% with level > 0.01 71.8 100 
Anti-diphtheria toxin antibody 
Geometric mean titre 0.02 2.94 
Minimum < 0.01 0.46 
Maximum 0.75 14.56 
% with level > 0.01 67.4 100 
Anti-pertussis antibody 
Geometric mean titre 48.71 422.77 
Minimum 10 10 
Maximum 2550 5110 
% with level 2 320 13.7 64.3 
% with 4-fold increase NA 54.6 
NA= not applicable. 
Table IV. Comparison between ICH and AP laboratory data -
anti-PRP antibody results before immunisation at 6 (pre-dose 1) 
and 18 weeks (post-dose 3), in children immunised with three 
doses of a DTP/PRP-T vaccine at 6, 10 and 14 weeks of age 
ICH (6wks) 
AP (6 wks) 
!CH (18 wks) 
AP (18 wks) 
GMT % ;:: 0.15 µg/ml % 2 1 µg/ml 
0. 11 31.1 9.7 
0.19 52.2 13.o 
1.45 95.7 65.2 
2.22 95.7 65.2 
!CH= Institute of Child Health, University of Cape Town; AP = Aventis Pasteur. 
administered according to the WHO EPI schedule. In addition, 
persistence of Hib antibodies was evaluated. 
A PRP antibody level 2 0.15 µg/ml is regarded as being a 
conservative threshold level of protection at any single time,2' 
while a level 2 1 µg/ml is regarded as providing long-term 
protection.25 In this study, 1 month after three doses of vaccine 
(i.e. at 18 weeks of age), almost all the ~hildren (95.5%) had an 
anti-PRP antibody titre greater than 0.15 µg/ml - indicative of 
good short-term protection - and 69.1 % had a titre greater 
than 1 µg/ml. The results are similar to those of a previous 
study from the same area, which evaluated the 
immunogenicity of two other Hib vaccines (HibTITER, Wyeth, 
USA and Pedvax, Merck Research Laboratories, USA) 
administered as a monovalent vaccine1'(Table V). The 
proportion of children in this study with anti-PRP-T levels 
greater than 1.0 µg/ml following the primary immunisation 
series was, however, slightly less than that reported from the 
Philippines,13 Israel15 and Chile18 with the same vaccine given at 
2, 4, and 6 months of age (Table V). 
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Table V. Comparative Hib immunogenicity data 4 weeks after 
thre~ doses of either monovalent or combined Hib conjugate 
vaccme 
% > 0.15 µg/ml % > 1 µg/ml 
Vaccination at 6, 10, 14 weeks 
of age 
This study 
DTP-PRP-T (TETRAct-HIB) 96 69 
Hussey et al. 1' 
PRP-OMP (PedvaxHIB) 94 79 
PRP-HbOC (HibTITER) 92 72 
Capeding1' 
PRP-OMP (Pedvax) 92 44 
PRP-HbOC (HibTITER) 88 62 
PRP-T (ActHib) 97 92 
Vaccination at 2, 4, 6 months 
of age 
Watemberg et al. 15 
DPT-PRP-T 98 94 
Avendano etal." 
DPT-PRP-T 100 98 
A decline in the anti-PRP GMT and the proportion of infants 
with anti-PRP antibody levels 2 0.15 and 2 1 µg/ml during the 
first 5 months post-immunisation (Table II) has been reported 
previously.26 The significance of these findings is, however, 
unclear. If an antibody level of 2 0.15 µg/ml is regarded as 
protective, then the data suggest that at least 25% of 
immunised children would be susceptible to Hib at about 9 
months of age. Since approximately 50% of cases of invasive 
Hib diseases in the Cape Town area occur in children over the 
age of 9 months,5 the data would suggest that a booster Hib 
vaccine at this age would be appropriate. On the other hand, 
this may not be necessary. Low levels of anti-PRP antibody 
(below 15 µg/ml) may in fact still be protective." In a recent 
study" in which a reduced response to PRP-T was observed on 
combination with an acellular pertussis vaccine, a vigorous 
response was observed when a dose of unconjugated PRP was 
administered to children at the age of 12 - 14 months, proving 
that these children had been immunologically primed. This 
anamnestic response, observed even in children with anti-PRP 
titres< 0.15 µg/ml, certainly suggests that such children are 
nevertheless protected against subsequent exposure to the Hib 
pathogen. In addition, routine Hib immunisation may protect a 
significant proportion of the 'susceptibles' indirectly through 
herd immunity by reducing circulation of the organism." 
All infants given three doses of TETRActHIB at 6, 10 and 14 
weeks of age achieved protective serum concentrations of anti-
tetanus and anti-diphtheria antibodies 1 month after the last 
dose of the vaccine. Approximately 65% of infants developed 
'immunity' to pertussis (i.e. level 2 320). This is slightly less 
than reported in other studies.15·13 One reason for this may have 
been the high pre-immunisation level of anti-pertussis 
antibodies, probably because of passively derived maternal 
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antibodies, which may have interfered with the immune 
response to the vaccine;29 the GMT (48) for pertussis agglutinins 
observed in this study cohort before immunisation was higher 
than that observed in other studies (generally less than 20) in 
which immunisation was started at 2 months of age.15'18 The 
implications of these observations are not clear. The precise 
relationship between pertussis antibody level and protection 
against disease is not known.'0'31 Nevertheless, the agglutination 
response following immunisation could be viewed as 
constituting a rough correlate of vaccine-induced immunity to 
pertussis. 
The vaccine was well tolerated by the infants, Observed 
reactions at the site of injection occurred in approximately 20% 
of children, while significant systemic reactions did not exceed 
15%. These adverse events rates were similar to those 
reported in a previous study from Cape Town using other Hib 
vaccines.14 
In conclusion, this study has shown that the DTP /PRP-T 
vaccine is safe, immunogenic and well tolerated in infants 
immunised at 6, 10 and 14 weeks of age. TETRActHIB is 
therefore suitable for inclusion in the WHO EPI schedule. 
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